Kolexia
Hospital Marie-Anne Hématologie
Hospital Marie-Anne
Hématologie
Centre Paoli-Calmettes
Marseille, France
86 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémie aigüe myéloïde Leucémies Leucémie myéloïde Syndromes myélodysplasiques Préleucémie Maladie aigüe Leucémie myélomonocytaire chronique Paraprotéinémies Récidive tumorale locale

Collaborateurs

Voir plus
Vey Norbert
Vey Norbert
Centre Paoli-Calmettes, Marseille, France
Recher Christian
Recher Christian
Hôpital Purpan, Toulouse, France
Cluzeau Thomas
Cluzeau Thomas
Hôpital De l'Archet, Nice, France
Garciaz Sylvain
Garciaz Sylvain
Centre Paoli-Calmettes, Marseille, France

Industries

Voir plus
Servier
4 collaboration(s)
Dernière en 2022
Astellas
4 collaboration(s)
Dernière en 2022
Novartis
3 collaboration(s)
Dernière en 2023
Abbvie
2 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Long-term survival of AML treated with intensive chemotherapy with extensive molecular data available.
Leukemia & lymphoma   08 février 2024
Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.
European journal of haematology   29 novembre 2023
Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome.
Bone marrow transplantation   03 novembre 2023
Molecular Relapse after First-Line Intensive Therapy in Patients with Core-Binding Factor and NPM1-Mutated Acute Myeloid Leukemia - a Filo Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
Clinical, Cytogenetic and Molecular Characterization of a 96 MDS and AML Cohort with TP53 Mutation
65th ASH Annual Meeting Abstracts   02 novembre 2023
FLT3 Ligand Kinetic Profile Predicts Response to Treatment and Event-Free Survival (EFS) in Adults with High-Risk MDS/CMML Receiving CPX-351: A GFM Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
Current Results of Intensive Therapy in Younger Adults with Acute Myeloid Leukemia (AML): The Large Randomized French Backbone Intergroup (BIG)-1 Study on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
65th ASH Annual Meeting Abstracts   02 novembre 2023
Poor Prognosis of SRSF2 Gene Mutations in Patients Treated with Venetoclax-Azacitidine (VEN-AZA) for Newly Diagnosed Acute Myeloid Leukemia. a Multicentric Real-Life Study of 117 Patients
65th ASH Annual Meeting Abstracts   02 novembre 2023
Preliminary Results of a Phase 1, First-in-Human Study of INA03, an Anti-CD71 Antibody-Drug Conjugate in Patients with Relapsed or Refractory (R/R) Acute Leukemias
65th ASH Annual Meeting Abstracts   02 novembre 2023
A Phase II Study of Single Agent Aspacytarabine (BST-236) in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Higher Risk Myelodysplastic Syndromes (R/R HR MDS)
65th ASH Annual Meeting Abstracts   02 novembre 2023